Current controversies in the management of metastatic colorectal cancer
Por:
Vera R, Alonso V, Gállego J, González E, Guillén-Ponce C, Pericay C, Rivera F, Safont MJ and Valladares-Ayerbes M
Publicada:
1 oct 2015
Resumen:
The factors affecting the decisions for the treatment for patients with metastatic colorectal cancer (mCRC) are related to the patient, the tumor, and the treatment itself. Both cetuximab and panitumumab are anti-EGFR monoclonal antibody options for patients with RAS wild-type tumors. Several trials comparing these agents with bevacizumab are analyzed in this paper. The liver is the most common site of metastases in patients with CRC, and perioperative chemotherapy has been shown to yield benefits in this setting. In the second-line treatment for mCRC, maintenance with bevacizumab after progression following first-line treatment is convenient in some groups of patients with mCRC. Also, aflibercept has demonstrated benefits in response rate, progression-free survival, and overall survival in second-line treatment, whereas regorafenib provides benefits to patients progressing on all standard therapies. Several novel therapeutic options for patients with mCRC are under development, and these are discussed.
Filiaciones:
Vera R:
Medical Oncology Department, Navarra Hospital Complex, Calle Irunlarrea, 3, 31008, Pamplona, Navarra, Spain.
Alonso V:
Medical Oncology Department, Miguel Servet University Hospital, Saragossa, Spain
:
Medical Oncology Department, Elche General University Hospital, Elche, Alicante, Spain
González E:
Medical Oncology Department, Virgen de las Nieves University Hospital, Granada, Spain
Guillén-Ponce C:
Medical Oncology Department, IRYCIS, Ramón y Cajal University Hospital, Madrid, Spain
Pericay C:
Medical Oncology Department, Sabadell University Hospital, Sabadell, Barcelona, Spain
Rivera F:
Medical Oncology Department, Marqués de Valdecilla University Hospital, Santander, Cantabria, Spain
Safont MJ:
Medical Oncology Department, General University Hospital of Valencia, Valencia, Spain
Valladares-Ayerbes M:
Medical Oncology Department, Biomedical Research Institute INIBIC, A Coruña University Hospital, A Coruña, Spain
|